Pfizer Inc. (NYSE:PFE) Holdings Lifted by South Dakota Investment Council

South Dakota Investment Council boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 33.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,246,648 shares of the biopharmaceutical company’s stock after buying an additional 312,410 shares during the quarter. Pfizer accounts for approximately 0.8% of South Dakota Investment Council’s investment portfolio, making the stock its 15th largest position. South Dakota Investment Council’s holdings in Pfizer were worth $35,891,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. NewSquare Capital LLC boosted its stake in Pfizer by 3.0% during the fourth quarter. NewSquare Capital LLC now owns 147,446 shares of the biopharmaceutical company’s stock valued at $4,190,000 after buying an additional 4,354 shares in the last quarter. Cutter & CO Brokerage Inc. boosted its stake in Pfizer by 473.4% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 104,331 shares of the biopharmaceutical company’s stock valued at $3,004,000 after buying an additional 86,137 shares in the last quarter. GAMMA Investing LLC bought a new position in Pfizer during the fourth quarter valued at about $342,000. Harbor Advisors LLC boosted its position in shares of Pfizer by 68.6% in the 4th quarter. Harbor Advisors LLC now owns 31,962 shares of the biopharmaceutical company’s stock valued at $920,000 after purchasing an additional 13,000 shares during the period. Finally, Ellenbecker Investment Group boosted its position in shares of Pfizer by 56.2% in the 4th quarter. Ellenbecker Investment Group now owns 13,222 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 4,756 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.06 during trading on Tuesday, hitting $26.32. 24,286,365 shares of the stock were exchanged, compared to its average volume of 42,105,117. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The company has a market capitalization of $149.04 billion, a price-to-earnings ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company’s fifty day simple moving average is $27.08 and its 200-day simple moving average is $28.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.